China Universal Asset Management Co. Ltd. Has $488,000 Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

China Universal Asset Management Co. Ltd. grew its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 11.5% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 12,637 shares of the company’s stock after buying an additional 1,308 shares during the period. China Universal Asset Management Co. Ltd.’s holdings in Protagonist Therapeutics were worth $488,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in PTGX. GAMMA Investing LLC lifted its holdings in Protagonist Therapeutics by 749.2% in the 3rd quarter. GAMMA Investing LLC now owns 552 shares of the company’s stock worth $25,000 after purchasing an additional 487 shares during the last quarter. FNY Investment Advisers LLC bought a new position in shares of Protagonist Therapeutics in the fourth quarter valued at approximately $38,000. Exchange Traded Concepts LLC acquired a new stake in shares of Protagonist Therapeutics in the third quarter worth $43,000. CWM LLC boosted its holdings in shares of Protagonist Therapeutics by 910.3% during the 3rd quarter. CWM LLC now owns 1,273 shares of the company’s stock worth $57,000 after buying an additional 1,147 shares during the period. Finally, Harvest Fund Management Co. Ltd acquired a new position in Protagonist Therapeutics in the 3rd quarter valued at $69,000. Institutional investors own 98.63% of the company’s stock.

Insider Buying and Selling at Protagonist Therapeutics

In other news, insider Arturo Md Molina sold 26,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $44.70, for a total value of $1,162,200.00. Following the transaction, the insider now directly owns 46,444 shares of the company’s stock, valued at $2,076,046.80. The trade was a 35.89 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Suneel Gupta sold 103,437 shares of the firm’s stock in a transaction on Monday, November 25th. The shares were sold at an average price of $46.04, for a total value of $4,762,239.48. Following the sale, the insider now directly owns 256,174 shares of the company’s stock, valued at $11,794,250.96. This represents a 28.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 209,863 shares of company stock worth $9,689,847 over the last three months. Company insiders own 5.40% of the company’s stock.

Protagonist Therapeutics Stock Performance

NASDAQ:PTGX opened at $37.80 on Monday. The company has a 50-day moving average of $39.68 and a 200-day moving average of $41.85. Protagonist Therapeutics, Inc. has a 52 week low of $24.22 and a 52 week high of $48.89. The company has a market capitalization of $2.25 billion, a price-to-earnings ratio of 14.21 and a beta of 2.23.

Protagonist Therapeutics (NASDAQ:PTGX) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.54) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.05. Protagonist Therapeutics had a return on equity of 34.68% and a net margin of 52.76%. The company had revenue of $4.68 million for the quarter, compared to the consensus estimate of $4.50 million. Sell-side analysts forecast that Protagonist Therapeutics, Inc. will post 2.28 EPS for the current year.

Wall Street Analyst Weigh In

PTGX has been the subject of a number of research analyst reports. HC Wainwright reissued a “buy” rating and set a $50.00 target price on shares of Protagonist Therapeutics in a research report on Tuesday, December 10th. BMO Capital Markets began coverage on Protagonist Therapeutics in a research note on Friday, December 6th. They set an “outperform” rating and a $62.00 target price for the company. The Goldman Sachs Group initiated coverage on Protagonist Therapeutics in a research report on Friday, December 6th. They issued a “neutral” rating and a $47.00 price target on the stock. StockNews.com downgraded shares of Protagonist Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, December 10th. Finally, Wedbush reiterated an “outperform” rating and set a $58.00 target price on shares of Protagonist Therapeutics in a research note on Tuesday, November 19th. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $53.78.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.